N‐phenacylthiazolium bromide decreases renal and increases urinary advanced glycation end products excretion without ameliorating diabetic nephropathy in C57BL/6 mice

Summary

[1]  Paul J Thornalley,et al.  Rapid hydrolysis and slow α,β-dicarbonyl cleavage of an agent proposed to cleave glucose-derived protein cross-links , 1999 .

[2]  K. Shimokata,et al.  Immunohistochemical detection of imidazolone and N(epsilon)-(carboxymethyl)lysine in aortas of hemodialysis patients. , 1998, Cellular and molecular biology.

[3]  M. Huijberts,et al.  Breakers of advanced glycation end products restore large artery properties in experimental diabetes. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[4]  V. Monnier,et al.  Immunohistochemical colocalization of glycoxidation products and lipid peroxidation products in diabetic renal glomerular lesions. Implication for glycoxidative stress in the pathogenesis of diabetic nephropathy. , 1997, The Journal of clinical investigation.

[5]  P. Verbeke,et al.  Accumulation of Advanced Glycation Endproducts in the Rat Nephron: Link with Circulating AGEs During Aging , 1997 .

[6]  B. Manjula,et al.  Chronic Dosing With Aminoguanidine and Novel Advanced Glycosylation End Product-Formation Inhibitors Ameliorates Cross-Linking of Tail Tendon Collagen in STZ-Induced Diabetic Rats , 1996, Diabetes.

[7]  G. Jerums,et al.  Effects of aminoguanidine in preventing experimental diabetic nephropathy are related to the duration of treatment. , 1996, Kidney international.

[8]  J. Bernhagen,et al.  An agent cleaving glucose-derived protein crosslinks in vitro and in vivo , 1996, Nature.

[9]  H. Sano,et al.  N (epsilon)-(carboxymethyl)lysine protein adduct is a major immunological epitope in proteins modified with advanced glycation end products of the Maillard reaction. , 1996, Biochemistry.

[10]  J. Baynes,et al.  N epsilon-(carboxymethyl)lysine is a dominant advanced glycation end product (AGE) antigen in tissue proteins. , 1995, Biochemistry.

[11]  G. Striker,et al.  Administration of AGEs in vivo induces genes implicated in diabetic glomerulosclerosis. , 1995, Kidney international. Supplement.

[12]  V. Monnier,et al.  Mechanism of Protein Modification by Glyoxal and Glycolaldehyde, Reactive Intermediates of the Maillard Reaction (*) , 1995, The Journal of Biological Chemistry.

[13]  R. Bucala,et al.  Immunohistochemical detection of advanced glycosylation end products within the vascular lesions and glomeruli in diabetic nephropathy. , 1995, Human pathology.

[14]  E. Friedman,et al.  Reactive glycosylation endproducts in diabetic uraemia and treatment of renal failure , 1994, The Lancet.

[15]  S. Genuth,et al.  The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. , 1993, The New England journal of medicine.

[16]  S. Kuwajima,et al.  Immunochemical Detection of Advanced Glycation End Products in Renal Cortex From STZ-Induced Diabetic Rat , 1993, Diabetes.

[17]  T. Lyons,et al.  Accumulation of Maillard Reaction Products in Skin Collagen in Diabetes and Aging a , 1992, Annals of the New York Academy of Sciences.

[18]  V. Monnier,et al.  Immunohistochemical detection of advanced glycosylation end products in diabetic tissues using monoclonal antibody to pyrraline. , 1992, The Journal of clinical investigation.

[19]  R. Bucala,et al.  Immunochemical detection of advanced glycosylation end products in vivo. , 1992, The Journal of biological chemistry.

[20]  V. Monnier,et al.  Chromatographic Quantitation of Plasma and Erythrocyte Pentosidine in Diabetic and Uremic Subjects , 1992, Diabetes.

[21]  E. Friedman,et al.  Advanced glycosylation end products in patients with diabetic nephropathy. , 1991, The New England journal of medicine.

[22]  T. Lyons,et al.  Age-dependent accumulation of N epsilon-(carboxymethyl)lysine and N epsilon-(carboxymethyl)hydroxylysine in human skin collagen. , 1991, Biochemistry.

[23]  K. Nicholls,et al.  Advanced glycosylation end-products in experimental murine diabetic nephropathy: effect of islet isografting and of aminoguanidine. , 1989, Laboratory investigation; a journal of technical methods and pathology.

[24]  J. Baynes,et al.  Nonenzymatic glucosylation and glucose-dependent cross-linking of protein. , 1983, The Journal of biological chemistry.

[25]  R. Osterby,et al.  Development of glomerular lesions in experimental long-term diabetes in the rat. , 1982, Kidney international.

[26]  K. Kivirikko,et al.  Heterogeneity of pepsin-solubilized human glomerular basement membrane collagen. , 1978, Nephron.

[27]  I. Bergman,et al.  The determination of hydroxyproline in urine hydrolysates. , 1970, Clinica chimica acta; international journal of clinical chemistry.

[28]  G. Striker,et al.  Strain differences rather than hyperglycemia determine the severity of glomerulosclerosis in mice. , 1998, Kidney international.

[29]  堀江勝智.  Immunohistochemical Colocalization of Glycoxidation Products and Lipid Peroxidation Products in Diabetic Renal Glomerular Lesions Implication for Glycoxidative Stress in the Pathogenesis of Diabetic Nephropathy(糖尿病糸球体病変における糖酸化物及び脂質過酸化物の局在: 糖尿病性腎症の発症進展における糖酸化ストレスの関与) , 1998 .

[30]  R. Kalluri,et al.  Early and advanced non-enzymatic glycation products in the pathogenesis of diabetic kidney disease. , 1997, Experimental nephrology.

[31]  P. Riederer,et al.  Determination of Advanced Glycation End Products in Serum by Fluorescence Spectroscopy and Competitive ELISA , 1997, European journal of clinical chemistry and clinical biochemistry : journal of the Forum of European Clinical Chemistry Societies.

[32]  池田和義.  N[ε]-(Carboxymethyl)lysine Protein Adduct Is a Major Immunological Epitope in Proteins Modified with Advanced Glycation End Products of the Maillard Reaction(カルボキシメチルリジン付加体はメイラード反応後期生成物の主要エピトープある) , 1997 .

[33]  J. Wetzels,et al.  The changing natural history of nephropathy in type I diabetes. , 1986, The American journal of medicine.

[34]  S. Colagiuri,et al.  The Diabetes Control and Complications Trial , 1983, Henry Ford Hospital medical journal.